﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Advanced Pharmaceutical Bulletin</JournalTitle>
      <Issn>2228-5881</Issn>
      <Volume>11</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2021</Year>
        <Month>01</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>A Novel Treatment of Schistosomiasis: Nano-Calcium Silicate Incorporating 5% Copper Oxide</ArticleTitle>
    <FirstPage>68</FirstPage>
    <LastPage>76</LastPage>
    <ELocationID EIdType="doi">10.34172/apb.2021.004</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Mohamed Fathallah</FirstName>
        <LastName>Abou El-Nour</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-7850-9734</Identifier>
      </Author>
      <Author>
        <FirstName>Sayed Hamed</FirstName>
        <LastName>Kenawy</LastName>
      </Author>
      <Author>
        <FirstName>Gehan T.</FirstName>
        <LastName>El-Bassyouni</LastName>
      </Author>
      <Author>
        <FirstName>Esmat Mahmoud Aly</FirstName>
        <LastName>Hamzawy</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-0984-9911</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/apb.2021.004</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2020</Year>
        <Month>01</Month>
        <Day>23</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2020</Year>
        <Month>04</Month>
        <Day>16</Day>
      </PubDate>
    </History>
    <Abstract>Purpose: Praziquantel (PZQ) is a well-known drug accredited by the World Health Organization (WHO) for the treatment of schistosomiasis. It shows poor efficiency in patients during the earliest infection phases. Therefore, the search for new alternative drugs was the intention of many researchers. Methods: In the current study, the effect of different concentrations (ranging from 0.07-10 μg∕mL) of calcium silicate (CS) containing 5% copper oxide [CS-5%CuO] on golden hamster infected by Schistosoma mansoni and Schistosoma haematobium (Egyptian strains) was evaluated in both in vitro and in vivo. To the best of our knowledge, this is a novel study in investigating the efficiency of CS-5%CuO against both strains of schistosomes. The worms of S. mansoni and S. haematobium were tested in RPMI-1640 medium in vitro. Results: The results declare that CS-5% CuO exhibited excellent anti-schistosomal activities on both in vitro and in vivo experiments for both Egyptians Schistosoma strains. The most potential effect of the CS-5% CuO was exhibited after 6 h by 10 μg∕mL with significant activity of (P value = 0.001). Conclusion: Therefore, CS-5%CuO may become an innovative treatment for the schistosomiasis.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Anti-schistosomal activity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CS-5%CuO-containing calcium silicate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">S. mansoni</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">S. haematobium</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>